executive
summary product
market diabetes
overview the science intellectual
property partners related
products ceo directors investor
relations publications Global Leader
Micro-encapsulation present
trials

 

executive summary

Altucell, Inc. is a cellular engineering and biotech company backed by sound research and science focused on fulfilling a large "unmet need" in cell, molecular and regenerative therapy for treatment of Diabetes and other autoimmune and neurodegenerative diseases. The company’s proprietary and unique technology overcomes the major barriers to transplantation by a novel strategy utilizing patented micro-encapsulation technology, enabling a transplantable, cell-based therapy that avoids detection and rejection by the immune system.

Mission

Develop improved treatments specifically for diabetes and other chronic diseases using a novel type of therapeutic: implanted cells shielded by proprietary biomaterials from immune attack and the foreign body response (fibrosis).

 

Vision

Apply Altucell’s cell engineering and delivery system-based platform to re-program and control dynamic protein delivery for the long-term treatment of debilitating diseases.

                                                                                                                 Altucell Therapeutics

The advantage of ALTuCELL’s patented encapsulation solution (Altsulin) is the potential to carry out the transplantation without requiring immunosuppressant therapy of transplanting porcine-derived Sertoli cells to drastically reduce or eliminate the need for insulin replacement therapy combined with the ability to carry regimens (see explanatory items on Sertoli cells below). ALTuCELL has secured the patent rights on encapsulation patents originating from this team of researchers at the University of Perugia, Italy, led by Dr. Riccardo Calafiore, M.D.